summari report sale
organ compar ex-fx basi came
ahead estim consensu
respect growth led rtg restor
therapi group mitg minim invas therapi group
strength emerg market em also solid
adj oper margin perspect deliv roughli
y/i expans translat non-gaap ep
ex-fx came consensu
fx lower tax rate model
guidanc front rais lower-end fiscal sale
guidanc rang organ vs previou guidanc
guid /- growth bottom-
line rais report ep guidanc
report ep mdt impli guidanc
report includ headwind
fx look ahead fiscal manag note
comfort current street estim includ consensu ep
commun except
expect deliv lrp long-range-plan initi
outlin compani investor day past june manag
note top-lin growth expect back-half weight
due cadenc new product launch next fiscal year
chang model increas fiscal sale estim
organ increas fiscal
non-gaap ep estim report
lower fiscal sale estim
organ non-gaap ep estim
report maintain price target
base cy ep estim
 recap report revenu
underli ex-fx ahead estim consensu
growth in-lin mdt guidanc
report ep ex-fx
consensu estim ep upsid vs
model mostli reflect lower tax rate vs
estim lower opex vs estim partli
off-set lower gross margin vs estim
wed note fx provid tailwind ep vs
guidanc neutral
continu next page
pleas see page rate definit import disclosur
requir analyst certif estimates/forecast
well fargo secur llc seek busi compani
cover research report result investor awar
firm may conflict interest could affect object report
investor consid report singl factor make
compani data secur llc estim reuter
ep exclud amort reflect combin follow
acquisit cov
compani data secur llc estim reuter
perform divis mix vs street expect cardiac vascular group sale
ex-fx miss consensu estim minim invas therapi
group revenu grew underli beat consensu forecast
restor therapi group sale increas ex-fx ahead consensu
forecast diabet revenu rose ex-fx miss consensu
forecast bigger pictur result busi larg consist mdt commentari
januari recal compani re-affirmed organ growth guidanc rang
organ note comfort mid-point rang vs higher-end previous
manag attribut chang soft cvg cardiac vascular group face
headwind lvad left ventricular assist devic dcb drug coat balloon expect
strength rtg mitg provid off-set weaker cvg growth
crhf growth slow mdt crhf cardiac rhythm heart failur busi declin ex-
fx compar growth high power perform mix
implant cardiovert defibril grow low-singl digit crt-d cardiac
pacemak grew mid-singl digit crt-p cardiac resynchron therapi pacemak sale
low double-digit mdt af atrial fibril solut grew mid-teen
diagnost reveal linq sale grew mid-singl digit global regard htwr lvad left
ventricular assist devic declin mid ww sale declin high
lvad weak primarili attribut approv abt pump dt destin
therapi receiv fda approv full quarter earlier expect
unfavor dynam lvad recent chang guidelin depriorit heart
transplant patient lvad bridge-to-transpl popul
csh growth led onyx evolut csh coronari structur heart revenu grew
organ modest deceler growth csh growth larg driven mid-
teen growth transcathet aortic valv replac tavr accord tavr grew
ou tavr grew ex-fx manag note see share gain
global market behind evolut separ de drug elut stent declin low-single-digit
global basi
apv growth remain strong apv aortic peripher vascular sale grew organ
compar perform quarter driven continu double-digit growth
endoven mid-teen dcb mid-teen manag said us dcb sale declin low-singl
digit ou sale grew driven japan look ahead manag anticip us
approv av arterialven fistula indic fiscal would least month
bdx lutonix av approv lutonix us approv btk below-the-kne expect later year
continu work opportun
pain franchis deceler sequenti led pain therapi sale grew y/i organ
meaning deceler result larg reflect spine
cord stimul growth high singl digit ww basi versu growth
attribut deceler tough y/i comp like slowdown market us sale
mid-to-high singl digit intern sale mid-teen overal
estim ww sale ex-fx includ us use
mdt result estim global market grew ex-fx meaning
slowdown vs level us market also grew y/i also deceler vs
y/i stack basi growth slowdown look magnifi ww
growth ex-fx vs vs elsewher
intervent pain grew mid-singl digit versu low-singl digit driven strength
spine growth flat y/i global spine sale flat y/i ex-fx roughli in-lin
growth segment core spine sale deliv growth consist result
second quarter low-singl digit declin us off-set similar rate growth outsid us
bmp bone morphogenet protein sale appear acceler sequenti flat growth
led growth us mid-singl digit outsid high-singl digit notabl spine
sale combin enabl technolog report neurosurgeri within brain divis
deliv growth includ growth us core spine acceler versu
level impli combin portfolio gain traction compani surgic
synergi strategi manag note mazorx stealth edit strong quarter placement
level impli gmed pre-announc estim gmed global placement
includ us
brain therapi double-digit brain therapi sale grew led high-teen growth
neurosurgeri neurovascular within neurosurgeri highlight high growth
capit equip sale driven stealthstat navig o-arm imag mazor robot
compani launch mazor stealth edit robot guidanc platform posit earli feedback
manag view strong capit equip sale lead indic futur growth spine
custom choos link futur spine implant purchas neurovascular saw broad strength
stroke franchis double-digit growth stent retriev flow divert neuro-access embol
product competitor also report double-digit organ growth neurovascular busi
highlight strong momentum atla stent system launch new aspir system
believ syk strong growth momentum neurosvascular like reflect continu market
strength bode well compani like
specialti therapi sale growth deceler specialti therapi sale
y/i repres deceler versu deceler appear led
pelvic health declin single-digit grew mid-teen ent growth slightli slower
mid-singl digit vs high-singl digit advanc energi acceler mid-teen
growth vs low double-digit
mitg growth stabl mitg sale total organ rel stabl
compar surgic innov si sale grew organ similar
continu strong perform advanc advanc stapl advanc
sale grew low-doubl digit help strength ligasur valleylab outperform
competitor jnj energi segment grew mid-singl digit busi continu lose
share advanc stapl grew high-singl digit help tri-stapl signia jnj
endocutt perform lag low-singl digit growth due tough yr/yr comp note
continu market convers minim invas surgeri mi contribut growth
highlight continu strong mid-teen si growth emerg market em respiratori
gastrointestin renal sale grew organ
respiratori grew high single-digit driven strength puritan bennett ventil nellcor
puls oximetri growth gi solut slow low double-digit growth mid-singl digit
growth region growth led emerg market ex-fx
us vs non-u develop market sale grew ex-fx vs nearli flat
track commerci launch sometim fiscal exact timing/loc remain confidenti
manag remark call appear increment posit us notabl held sever
submiss meet regulatori bodi around world includ fda surgeon
use mdt ra platform manag note call initi experi respect
system perform workflow posit compani said give mani
detail closer launch competit reason manag continu expect fairli modest
revenu contribut fiscal greater impact fiscal
diabet growth slow due tough y/i comparison global diabet sale
y/i organ repres sequenti deceler due tough
y/i comparison us pump sale recal neg growth last year due
sensor suppli constraint stronger growth due increas capac catch
addit anniversari consum revenu out-of-warranti convers
anima transit quarter one last larg commerci payer approv
reimburs quarter last year despit tough comp worth note
post sequenti growth segment advanc insulin manag aim deliv
mid-singl digit growth emerg technolog et deliv y/i growth fiscal
expect diabet franchis grow low-to-mid teen includ flat y/i growth
reflect anoth tough prior year comp manag believ growth repres bottom
diabet growth expect acceler thereaft said expect diabet grow
corpor averag separ announc earlier yesterday receiv
breakthrough devic design pcl person close loop insulin pump system fda
post anoth quarter strong em growth emerg market em revenu
y/i ex-fx slightli ahead growth manag note strong em
growth across geographi busi region south asia grew fastest ex-fx
follow middl east africa china eastern europ grew southeast
asia latin america overal em revenu account
revenu last quarter in-lin estim large-cap med-tech median em
exposur worth note mdt em growth ex-fx large-cap
med-tech median growth rate roughli expect maintain double-digit growth
em behind increas penetr exist approv therapi increas demand
fiscal outlook rais earlier yesterday rais lower-end fiscal sale
guidanc rang organ vs previou guidanc expect fx
headwind fiscal vs headwind previous impli
report revenu rang report mdt fiscal sale outlook
busi follow cvg expect grow mitg expect grow /- rtg
expect grow diabet expect grow low mid-teen regard
margin continu target oper margin improv ex-fx fiscal
bottom-lin rais report ep guidanc report
mdt full-year guidanc impli /- organ growth non-gaap ep
report expect fx headwind sale headwind
thought fiscal call continu shift street focu fiscal
mdt commentari larg unchang remark compani provid earli januari
recal part januari updat said expect adj ep growth
compani goal plan period larg due anticip step tax rate
ep outlook disappoint view manag said annual organ growth
op margin improv lrp long-rang plan goal remain intact regard
cadenc growth said expect top-lin growth next fiscal year back-end load given
expect time compani new product launch y/i comp compani note expect
guidanc /- effect floor top-lin growth move
larg cap med-tech organ growth remain robust report tuesday
morn aggreg growth rate larg cap med-tech name see figur
analysi indic world-wide organ ex-fx growth y/i compar
growth stack two-year basi modestli ahead
highest level seen past three year see figur look organ
growth full-year basi growth acceler cy cy
note organ growth adjust fx acquisitions/divestitur sell day meaning
note organ growth adjust fx acquisitions/divestitur sell day meaning
organ growthfi med-tech pf cfn average excl growth year stack med-tech pf cfn average excl medic technolog
price target nc
price target assum cy cash ep estim risk includ
weak key end market greater share loss model delay product launch
believ deliv averag organ growth due lull major new product launch
combin competitor headwind
found minneapolis-bas lead global medic technolog compani
focus provid therapi chronic diseas compani four primari busi cardiac
vascular restor therapi minim invas therapi diabet revenu
plc incom statementin million except per share datafisc year end etot net currenc y-i expensesresearch oper incomenet interest expens amort incom tax incom adj continu year-to-year incom year-to-year incom dilut share year-to-year compani report secur llc estim plc
